ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Computational-experimental identification of bioactive component combinations from Salvia miltiorrhiza for cardiovascular protection.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cardiovascular dysfunction represents a major global health challenge due to its high morbidity and mortality, underscoring the urgent need for more efficient drug discovery paradigms. This study developed and applied an integrative computational-experimental strategy to systematically explore and prioritize bioactive component combinations with crude extract-comparable activity (BECC) from traditional herbs, using Salvia miltiorrhiza (Danshen, DS) as a representative case relevant to cardiovascular protection. LC-MS/MS-based exposure-informed metabolite profiling, reverse target fishing, molecular docking, pharmacophore analysis were integrated to develop multidimensional component-target networks. Through this framework, 139 potential targets associated with 26 bioactive components and 41 metabolites were collected. Target activity spectrum (TAS) and pharmacodynamic activity spectrum (PAS) analyses were further employed to prioritize BECC, comprising rosmarinic acid, salvianolic acids A and B, cryptotanshinone, and tanshinone I. Within the tested in vitro systems and concentration ranges, this combination exhibited pharmacological activity profiles that were broadly comparable to those of the crude DS extract, as evaluated in three cardiovascular-relevant cellular models, supporting its potential as a representative multi-component candidate. In conclusion, this study provides a proof-of-concept case study demonstrating an integrative strategy to narrow complex herbal extracts into defined component combinations for subsequent translational evaluation, offering a methodological reference for studying the multi-component basis of traditional medicines in the context of cardiovascular-related research.
Indexed as
Identifiers
41591491What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.